VIR (Vir Biotechnology) Margin of Safety % (DCF Dividends Based): N/A (As of Aug. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VIR Vir Biotechnology Inc VIR
52 GF Score
Price $9.50
GF Value $42.20
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Vir Biotechnology Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Vir Biotechnology's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

VIR vs AVBP, XNCR, SEPN: Margin of Safety % (DCF Dividends Based) Comparison

For the Biotechnology subindustry, Vir Biotechnology's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vir Biotechnology Margin of Safety % (DCF Dividends Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vir Biotechnology's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Vir Biotechnology's Margin of Safety % (DCF Dividends Based) falls into.


VIR
52GF Score
Vir Biotechnology Inc VIR
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Vir Biotechnology (VIR) Overvalued in 2026?

Based on GuruFocus' analysis, Vir Biotechnology stock appears to be undervalued. The current stock price of $9.50 is trading 77.5% below its estimated GF Value™ of $42.20. GuruFocus considers Vir Biotechnology to be Possible Value Trap.

Key valuation signals for VIR:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: $42.20 vs. price of $9.50 (77.5% below fair value)
  • GF Score™: 52/100 with 5 warning signs

No single metric tells the full story. See the VIR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vir Biotechnology Business Description

Address 1800 Owens Street, Suite 900, San Francisco, CA, USA, 94158
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
52GF Score

Get the complete analysis for VIR

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.50
Price
$42.20
GF Value